久久久精品456亚洲影院,国产精品九九,午夜影院福利,尻逼影院

Press Release

2025

2024

2023

2022

2021

2020

2019

2018

2017

Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor

Mabwell and Insilico Medicine Announce Strategic Collaboration to Empower R&D of ADC with AI

Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mabwell publishes the preclinical research results of integrin-αvβ8-targeting antibody in the renowned journal

Mabwell's Nectin-4 Targeted ADC 9MW2821 Combination Therapy Demonstrates 87.5% ORR and Granted CDE Breakthrough Therapy Designation

Previous 1 2